Reply to thread

Message: <blockquote data-quote="imhotep" data-source="post: 28313664" data-attributes="member: 562115">The obvious explanation is insufficient drug exposure. The drug regime used was not enough to stop all viral replication. It's termed a Covid-19 rebound.The 7-day and 30-day COVID-19 rebound rates after Paxlovid treatment were 3.53% and 5.40% for COVID-19 infection, 2.31% and 5.87% for COVID-19 symptoms, and 0.44% and 0.77% for hospitalizations. The 7-day and 30-day COVID-19 rebound rates after Molnupiravir treatment were 5.86% and 8.59% for COVID-19 infection, 3.75% and 8.21% for COVID-19 symptoms, and 0.84% and 1.39% for hospitalizations. After propensity-score matching, there were no significant differences in COVID-19 rebound risks between Paxlovid and Molnupiravir though they act differently.</blockquote>

Top Bottom